Related Experiment Video
Updated: Jun 1, 2026
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
Published on: August 1, 2018
Expression of Fas in female reproductive tract tumors
Abstract:
Fas, a cell surface receptor, mediates cell death by means of apoptosis in a variety of cell types. We attempted to detect Fas within plasma membrane isolated from surgically removed female reproductive tract tumors. Eight of 9 endometrial carcinomas and all ovarian carcinoma tested expressed Fas mRNA as assessed by RT-PCR using oligonucleotide primers according to published sequences. Immunoblotting of membrane proteins with the specific antibodies detected an immunoreactive Fas in 15 of the 16 tumors tested. In contrast, none of 9 uterine cervical carcinomas demonstrated Fas expression. Fas was expressed in a wide range of the carcinomas originating from the uterine endometrium and ovary, but not in the uterine cervix-derived tumors. Despite a poorly understood processes of apoptosis at present, this may suggest frequent expression of Fas in adenocarcinoma histologic types.
Insights
Researchers investigated Fas receptor expression in female reproductive tract tumors. Fas was frequently detected in endometrial and ovarian carcinomas but absent in cervical carcinomas, suggesting its role in adenocarcinoma development.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Fas is a cell surface receptor crucial for initiating apoptosis (programmed cell death).
- Apoptosis plays a vital role in regulating cell numbers and eliminating damaged cells.
- Understanding Fas expression in gynecological cancers is important for potential therapeutic strategies.
Purpose of the Study:
- To determine the presence and expression levels of Fas in various female reproductive tract tumors.
- To investigate the correlation between Fas expression and specific tumor types, including endometrial, ovarian, and cervical carcinomas.
- To explore the potential implications of Fas expression in the context of adenocarcinoma histology.
Main Methods:
- Plasma membranes were isolated from surgically removed tumors.
- Reverse transcription polymerase chain reaction (RT-PCR) was used to detect Fas mRNA.
- Immunoblotting with specific antibodies was employed to detect Fas protein expression.
Main Results:
- Fas mRNA was detected in 8 of 9 endometrial carcinomas and all tested ovarian carcinomas.
- Immunoreactive Fas protein was found in 15 of 16 tested tumors.
- No Fas expression (mRNA or protein) was observed in any of the 9 uterine cervical carcinomas.
Conclusions:
- Fas is frequently expressed in endometrial and ovarian adenocarcinomas.
- Fas expression is notably absent in uterine cervical carcinomas.
- These findings suggest a potential role for Fas in the pathogenesis of specific gynecological adenocarcinomas.
